Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It treats diabetic macular edema in adults.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology centres, pharmacies and clinics worldwide.

Iluvien is a corticosteroid implant used to manage ocular conditions characterized by chronic inflammation and fluid accumulation.

Diabetic macular edema (center‑involved): reduces retinal swelling and improves visual acuity. Diabetic macular edema (persistent after anti‑VEGF therapy): provides sustained anti‑inflammatory control. Chronic non‑infectious posterior uveitis: controls intra‑ocular inflammation and limits macular edema.

Iluvien may be associated with ocular adverse reactions that vary in frequency and severity.

Common Side Effects: - Increased intraocular pressure: may require topical pressure‑lowering therapy. - Cataract formation: accelerated progression in phakic eyes. - Vitreous floaters: transient visual disturbances after implantation. - Ocular discomfort or pain: typically mild and self‑limiting. - Conjunctival hemorrhage: small bleed at injection site. - Reduced visual acuity: temporary changes during the early post‑implant period.

Serious or Rare Side Effects: - Endophthalmitis: severe intra‑ocular infection requiring urgent treatment. - Retinal detachment: rare but vision‑threatening complication. - Implant migration: movement of the device to an unintended intra‑ocular location. - Severe ocular hypertension: may need surgical intervention. - Uveitis flare: paradoxical inflammation in susceptible patients. - Optic nerve damage: extremely rare, associated with uncontrolled pressure.

Prior to Iluvien implantation, clinicians should evaluate ocular health and systemic factors. - Monitor intraocular pressure: schedule regular tonometry assessments. - Assess cataract status: inform phakic patients of potential lens opacification. - Avoid in active ocular infection: postpone implantation until infection resolves. - Use caution in glaucoma patients: heightened risk of pressure spikes. - Counsel on need for long‑term ophthalmic follow‑up: detect late‑onset effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct light.

Iluvien may interact with other ocular or systemic therapies that influence steroid exposure or intra‑ocular pressure.

Major Interactions (Avoid): - Systemic corticosteroids: additive systemic glucocorticoid effects. - Concurrent intra‑ocular steroids: increased risk of ocular hypertension. - Strong CYP3A4 inhibitors: potential elevation of intra‑ocular fluocinolone levels.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: may raise risk of corneal complications. - Anticoagulants: heightened bleeding risk during injection procedure. - Glaucoma medications: may require dose adjustment if intra‑ocular pressure rises. - Anti‑VEGF agents administered within 4 weeks: monitor for overlapping inflammation control.